Debjit Bhowmik, Rishab Bhanot, Darsh Gautam, Parshuram Rai, K.P. Sampath Kumar
Debjit Bhowmik1*, Rishab Bhanot1, Darsh Gautam1, Parshuram Rai1, K.P. Sampath Kumar2
1Himachal Institute of Pharmaceutical Education and Research, Nadaun, Hamirpur, H.P.
2Department of Pharmacy, Coimbatore Government Medical College, Coimbatore
Volume - 9,
Issue - 3,
Year - 2017
Telmisartan is a ACE inhibitor anti-hypertensive drug. Hence, in the present work, Telmisartan fast dissolving tablets will be prepared by using different super disintegrating agents. The amount of drug that is subject to first pass metabolism is reduced as compared to mouth dissolving tablets. Orally disintegration tablets contain wide variety of pharmaceutical active ingredients covering many therapeutic categories. The time for disintegration of orally disintegrating tablets are generally considered less than one minute. Orally disintegrating tablets are characterized by high porosity, low density and low hardness. The blend was examined for the pre-compressional parameters and post-compression parameters. Drug compatibility with excipients was checked by FTIR studies. The values of pre-compression parameters evaluated were within prescribed limits and indicated good free flowing property. In all the formulations, friability is less than 1%, indicated that tablets had a good mechanical resistance. Drug content was found to be in the range of 98 to 102%, which is within acceptable limits. Hardness of the tablets was found to be in the range of 3-4 Kp. The in vitro dispersion time was found to be in the range of 38-112sec with rapid in vitro dissolution within 3 min. No chemical interaction between drug and excipients was confirmed by FTIR studies. The drug release from tablets of Telmisartan prepared by direct compression showed that 98.20% drug release within 15 minutes.
Cite this article:
Debjit Bhowmik, Rishab Bhanot, Darsh Gautam, Parshuram Rai, K.P. Sampath Kumar. Formulation and Evaluation of Telmisartan Fast Dissolving Tablets by Direct Compression Method. Res. J. Pharm. Dosage Form. & Tech. 2017; 9(3): 131-139. doi: 10.5958/0975-4377.2017.00022.2